

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS : MEIKLE, Peter et al.
U.S. Application No. : Not Yet Assigned
U.S. Application Filed : Herewith
INT'L APPL'N NO. : PCT/AU2005/000461
INT'L FILING DATE : 31 Mar. 2005 (31.03.2005)
FOR : SCREENING FOR LYSOSOMAL STORAGE DISEASE
STATUS

MS PCT
Commissioner for Patents
P.O. BOX 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

S I R:

Pursuant to the Duty to Disclose under 37 C.F.R. §1.56(a), applicants enclose herewith a copy of Form PTO-1449 listing documents relevant to the background of the invention described and claimed in the above-identified application. Also enclosed is a copy of the International Search Report in counterpart International Application No. PCT/AU2005/000461.

Applicants respectfully request that the Examiner consider the enclosed references in determining the patentability of the claimed invention. Applicants also request that the Examiner return a copy of enclosed Form PTO-1449 in due course with initials or other markings thereon indicating that the enclosed references have been so considered.

Respectfully submitted,

COLEMAN SUDOL SABONE, P.C.

Dated: September 27, 2006

By: 

Henry D. Coleman
Reg. No. 32,559

714 Colorado Ave.
Bridgeport, Connecticut 06605-1601
203-366-3560

INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Att'y Ref: A20-079	Serial No:
	Applicant: MEIKLE, Peter et al.	
	Filing Date:	Art Unit:

United States Patent Documents						
Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date

Foreign Patent Documents							
Examiner Initial	Publication Number	Publication Date	Country	Class	Subclass	Translation	
						Yes	No

Examiner Initial	Other Documents (by Author, Date, Publication, Pertinent Pages, Title, Etc.)
	Whitfield <i>PD et al</i> (2002) <i>Mol. Gen & Metabolism</i> 75: 46-55 "Correlation among Genotype, Phenotype and Biochemical Markers in Gaucher Disease: Implications for the Prediction of Disease Severity"
	Cable <i>WJL et al</i> (1982) <i>Neurology (Ny)</i> 32: 1139-1145 "Fabry disease: Detection of heterozygotes by examination of glycolipids in urinary sediment"

Examiner:	Date Considered:
<small>EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered; Include a copy of this form with next communication to the applicant.</small>	

	Fujiwaki T <i>et al</i> (2002) <i>Brain & Development</i> 24:170-173 "Application of delayed extraction matrix-assisted laser desorption ionization time-of-flight mass spectrometry for analysis of sphingolipids in cultured skin fibroblasts from sphingolipidosis patients"
	Fujiwaki T <i>et al</i> (2002) <i>J. Chromatography B</i> 776: 115-123 "Application of delayed extraction-matrix-assisted laser desorption ionization time-of-flight mass spectrometry for analysis of sphingolipids in pericardial fluid, peritoneal fluid and serum from Gaucher disease patients"
	Oshima M <i>et al</i> (1990) <i>Bioch et Biophys Ada</i> 1043: 157-160 "Urinary neutral glycosphingolipid analysis of patients with Fabry's disease; rapid isocratic elution from high-performance liquid chromatography as per-o-benzoyl derivatives"

Examiner:	Date Considered:
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered; Include a copy of this form with next communication to the applicant.	